Ascendis Pharma As (ASND) SEC Filing 20-F Annual report for the fiscal year ending Wednesday, December 31, 2014

Ascendis Pharma As

CIK: 1612042 Ticker: ASND

View differences made from one year to another to evaluate Ascendis Pharma As's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 20-F Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Ascendis Pharma As.


Assess how Ascendis Pharma As's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Ascendis Pharma As's Definitive Proxy Statement (Form DEF 14A) filed after their 2015 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors



Material Contracts, Statements, Certifications & more

Ascendis Pharma As provided additional information to their SEC Filing as exhibits

Ticker: ASND
CIK: 1612042
Form Type: 20-F Annual Report
Accession Number: 0001193125-15-107137
Submitted to the SEC: Thu Mar 26 2015 5:01:15 PM EST
Accepted by the SEC: Thu Mar 26 2015
Period: Wednesday, December 31, 2014
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: